NovoCure Limited (NVCR) Financial Statements
NovoCure Limited (NVCR) reported trailing twelve-month revenue of $699.2M (up 11.0% year on year) and net income of -$148.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$25.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NVCRNovoCure LimitedFollow NVCR — free
—
Price chart with a free account
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 4 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.03 | 0.08 | 0.18 | 0.25 | 0.35 | 0.49 | 0.54 | 0.54 | 0.51 | 0.61 | 0.66 | 0.70 | |
| Gross profit | 0.01 | 0.04 | 0.12 | 0.17 | 0.26 | 0.39 | 0.42 | 0.42 | 0.38 | 0.47 | 0.49 | 0.53 | |
| Research & development | 0.04 | 0.04 | 0.04 | 0.05 | 0.08 | 0.13 | 0.20 | 0.21 | 0.22 | 0.21 | 0.22 | 0.22 | |
| Operating income | -0.10 | -0.12 | -0.04 | -0.03 | -0.00 | 0.03 | -0.04 | -0.09 | -0.23 | -0.17 | -0.15 | -0.15 | |
| Pre-tax income | -0.11 | -0.12 | -0.05 | -0.05 | -0.01 | 0.02 | -0.05 | -0.08 | -0.19 | -0.13 | -0.14 | -0.15 | |
| Income tax | 0.00 | 0.01 | 0.01 | 0.02 | -0.00 | -0.00 | 0.01 | 0.01 | 0.02 | 0.04 | -0.00 | -0.00 | |
| Net income | -0.11 | -0.13 | -0.06 | -0.06 | -0.01 | 0.02 | -0.06 | -0.09 | -0.21 | -0.17 | -0.14 | -0.15 | |
| Diluted EPS ($) | -3.67 | -1.54 | -0.70 | -0.69 | -0.07 | 0.18 | -0.56 | -0.88 | -1.95 | -1.56 | -1.22 | -1.30 | |
| Diluted shares (bn) | — | — | — | — | — | 0.109 | 0.103 | 0.105 | 0.106 | 0.108 | 0.111 | — |
USD billions · SEC XBRL
NovoCure Limited — questions
- What is NovoCure Limited's revenue?
- $699.2M over the twelve months to 2026-06-30, up 11.0% year on year, from its 10-Q and 10-K filings.
- What is NovoCure Limited's net income?
- -$148.6M over the twelve months to 2026-06-30.
- What is NovoCure Limited's free cash flow?
- -$25.4M over the twelve months to 2026-06-30.
- What are NovoCure Limited's diluted earnings per share?
- $-1.30 over the twelve months to 2026-06-30.
Every figure on this page comes from NovoCure Limited's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.